Drug Profile
Research programme: antibacterials - Cantab Anti-infectives
Alternative Names: NVB333; PolymyxinsLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Novacta Biosystems
- Developer Cantab Anti-infectives; Novacta
- Class Peptides; Proteins
- Mechanism of Action Cell wall inhibitors; Growth inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gram-negative infections; Gram-positive infections
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for preclinical development in Gram-negative-infections in United Kingdom
- 16 Jul 2016 No recent reports of development identified for preclinical development in Gram-positive-infections in United Kingdom (Parenteral)
- 25 Jan 2016 Preclinical trials in Gram-negative infections in United Kingdom (unspecified route) before January 2016